Mhs_oncologyclinicaltrials.pages

ONCOLOGY CLINICAL RESEARCH TRIALS -2009
A Randomized, double blind, Placebo-Controlled Phase III trial for Postmenopausal Women with ER, PgR+ Advanced Breast CA.With or without Inhibition of EGF & Her2 Growth Factor Receptors; Neo-Adjuvant Phase III study comparing 16-18 wks of neoadjuvant Exemestane, Letrozole. Or Anastrozole. Postmenopausal Stage II & III ER A Randomized Phase III trial comparing three Chemotherapy regimens with, without, Bevacizumab for Her2neu negative Breast Resected by lumpectomy, tumor size < 3.9 cm, and no more than 3 positives nodes: Whole Breast irradiation or Partial breast irradiation. Ineligible: > 50 yrs of age with DCIS; or with invasive To determine the Efficacy of 5 yrs of Letrozole Compared to Placebo in Pts. 5 yrs of Hormonal Therapy consisting of an AI or Tamoxifen followed by an AI in prolonging DFS Postmenopause Phase III study; Invasive CA; Her2 positive or negative: dose dense Node positive regimens: AC (q 14 days, 4 vs. 6 cycles) Vs Taxol (4 vs. 6 cycles) + ER/PR +; Node negative, Treatment type based on ONCOTYPE DX Assay. Primary group Oncotype risk score 11-25 = Arm B Hormonal Therapy or Arm C Chemo plus Hormonal Therapy. Secondary Study Group Oncotype Risk Score < 11, = Arm A Hormonal Therapy. Oncotype Risk Score > 25 = Arm D Phase III Trial of Continuous Schedule AC + G Vs. q 2 wk schedule AC, followed by Paclitaxel given either q 2 wks or weekly for 12 wks as Post-op Adjuvant Therapy in node + or High-Risk Node Phase III Randomized trial of Anastrozole Vs. Anastrozole and Fulvestrant as first line therapy for Postmenopausal women.
A Phase III Study of Bisphosphonates as Adjuvant therapy for Primary Breast Cancer. No Mets. Resected. Primary Invasive, Must Suppression of Ovarian Function Trial. Premenopausal (estradiol E2) resected breast CA, ER+ or PR+, with or without chemo. Remains Premenopausal post chemo (adj or neo). Node + (0; 1 or A Phase III Randomized trial of FOLFOX vs. FOLFOX plus Cetuximab (Erbitux) Stage III after curative resection. Node positive A Phase III Randomized trial of adjuvant chemo radiation after resection. Stomach or Gastro-Esophageal. Extension beyond muscularis propria or nodule involvement: Intergroup Randomized Phase III study of Post-Op Oxaliplatin, 5- Fluorouracil & Leucovorin vs. Oxaliplatin, 5-Fluorouracil, Leucovorin & Bevacizumab for Pt’s with Stage II or III Rectal Ca receiving Pre-Op Chemo radiation. No Mets. < 12 cm from the anal Stage II or III. < 12 cm from the anal verge. Pre-Op RT/ Capecitabine vs. Pre-op RT & CIVI 5 FU.
First line, FOLFOX or FOLFIRI plus Cetuximab or Bevacizumab or A Randomized, Double-Blind Phase III trial of adjuvant Sunitinib vs. Sorafenib vs. Placebo for resected Renal Cell Ca Stage IB2, IIA, IIB, IIIB & IVA Cervical Ca limited to the Pelvis. A Phase III Randomized trial of weekly Cisplatin & Radiation vs. Cisplatin & Tirapazmine &Radiation.
HEAD &
LEUKEMIA CTSU/SWOG
A Phase III study of the addition of Gemtuzumab Ozogamicin (Mylotarg) Induction therapy Vs. Standard Induction with Daunomycin & Cytosine Arabinoside followed by Consolidation and subsequent randomization to post-consolidation therapy with Gemtuzumab Ozogamicin (Mylotarg) or no additional therapy for Patients under age 61 with previously untreated De Novo AML Cytogenetic study in leukemia patients. Patient must be registered on another SWOG Leukemia study to be eligible.
Leukemia centralized reference laboratories & tissue repositories- consent to perform cellular and molecular studies in leukemia patients. Patient must be registered on another SWOG Leukemia Phase III chemoprevention trial of Selenium Supplementation. Molecular Epidemiology case series study of Non-Small Cell Lung Ca in smoking & non-smoking women and men. Within 120 days of LYMPHOM CTSU/CALGB
Phase III Randomized trial of R-CHOP vs. Dose adjusted EPOCH-R with Molecular profiling in untreated De Novo diffuse large B-cell A Phase III Randomized trial of Sentinel Lymphadenectomy and complete lymph node dissection Vs. sentinel lymphadenectomy alone. Cutaneous with molecular or histopathological evidence of metastases in the sentinel node. Breslow thickness of 1.20 mm or greater and Clark level III, or Clark level IV and V

Source: http://mhchildren.com/wps/wcm/connect/fbc86e0040f58637a55aff74e1e6f338/MHS_OncologyClinicalTrials.pdf?MOD=AJPERES&CACHEID=fbc86e0040f58637a55aff74e1e6f338